CardioFocus HeartLight® Endoscopic Ablation System Highlighted at Frankfurt Atrial Fibrillation Academy 2013

CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that its technology will be discussed at the 3rd Annual Frankfurt Atrial Fibrillation Academy (FAFA), to be held March 9th in Frankfurt, Germany. The FAFA Symposium, chaired by KR Julian Chun, MD and Boris Schmidt, MD of Cardioangiologisches Centrum Bethanien (CCB) in Frankfurt, will highlight the latest innovations and research in atrial fibrillation therapy. The meeting will feature data presentations and live case broadcasts from cardiologists throughout Germany, as well as clinical discussion on topics such as the use of catheter ablation as a first-line therapy, preventing AF recurrence after ablation and the role of interventional procedures in AF treatment. “In Germany alone there are over one million people suffering with AF. As that population grows, it is important to continually evaluate available techniques and technologies and their clinical impact. The focus of the FAFA meeting is on fostering discussion around the current treatment challenges as well as new advances, such as the HeartLight system, that may enable physicians to improve therapy outcomes,” said Dr. Chun. “AF has historically been very difficult to effectively treat, whether through drug therapy or advanced ablation techniques. We look forward to collaborating with our peers to further hone our understanding of this challenging condition,” said Dr. Schmidt. HeartLight is the first catheter ablation system to incorporate an endoscope, laser energy source and compliant balloon catheter to enable direct visualization of the beating heart while creating a more efficient, durable and precise cardiac ablation. It is CE marked and clinically available in Europe and Australia, and currently the focus of a pivotal trial in the U.S., expected to complete enrollment this year. The team at CCB in Frankfurt has performed over 180 cardiac ablation cases with the technology to date. To learn about CardioFocus and its HeartLight technology, please visit www.CardioFocus.com. More information on the FAFA Symposium can be found at www.fafa-symposium.de. About CardioFocus, Inc. CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation. The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe and in Australia. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA. For more information on the company and its technology, please visit www.CardioFocus.com. The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.